1. Scrip
  2. >>Business

CureVac Launches IPO, Adds To Big 2020 Cash Haul

 
• By Mandy Jackson

CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.

Well-dressed man standing in a big room in front of big silver dollar sign with blue sky inside it. Symbol of power, money and freedom. Targeting success and happiness. Back view.
Its mRNA vaccine against SARS-CoV-2 put CureVac in the stock market spotlight • Source: Shutterstock

CureVac BV might have exploited booming investor interest in messenger RNA (mRNA) vaccines with a massive initial public offering in the US to fund its clinical-stage vaccine against SARS-CoV-2, but its offering on 14 August was relatively modest. The company grossed $213m from the sale of 13.3 million shares at $16 each, although it has now raised more than $1bn in 2020 after financings earlier this year.

Tubingen, Germany-based CureVac has been working on mRNA vaccines for two decades but its work now on a COVID-19 vaccine has thrust the company into a brighter international spotlight. Its earlier work and its efforts against the novel coronavirus have had the backing of entrepreneur Dietmar Hopp, co-founder of the software giant SAP, who remains CureVac’s largest shareholder even after the IPO

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.